Ensysce Biosciences

Ensysce Biosciences, Inc. is a clinical-stage biopharmaceutical company, which engages in the development of solutions for severe pain relief while reducing the fear of and the potential for misuse and overdose. The firm's Trypsin Activated Abuse Protection and Multi-Pill Abuse Resistance platforms are in the process of developing a new class of powerful, tamper-proof opioids that prevent both drug abuse and overdoses. The company was founded in April 2003 and is headquartered in La Jolla, CA.

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Partnership further expedites Ensysce's development pipeline NOTTINGHAM, England , Aug. 31, 2022 /PRNewswire/ -- Ensysce Biosciences, Inc. ("Ensysce" or the "Company") (NASDAQ: ENSC) (OTC PINK: ENSCW), a clinical-stage biotech company applying transformative chemistry to improve prescription drug safety, and Quotient Sciences, a drug development and manufacturing accelerator, today announced a partnership to support the development and clinical testing of PF614-MPAR.   PF614-MPAR is a novel opioid combination product for the potential treatment of chronic pain that is designed to prevent both abuse and overdose.

Ensysce Biosciences and Quotient Sciences Announce a Partnership on the Development and Clinical Testing of Ensysce's PF614-MPAR, a Novel Opioid Designed to Prevent Abuse and Overdose

SAN DIEGO, CA / ACCESSWIRE / August 31, 2022 / Ensysce Biosciences, Inc. ("Ensysce" or the "Company") (NASDAQ:ENSC)(OTC PINK:ENSCW), a clinical-stage biotech company applying transformative chemistry to improve prescription drug safety to reduce abuse and overdose, today announced the launch of the new Ensysce website at www.ensysce.com. The Company's updated website highlights the TAAPTM and MPARTM technology platforms, the depth of the team, and our truly unique products for the treatment of severe pain.

Ensysce Biosciences Debuts Redesigned Company Website to Highlight its TAAP(TM) and MPAR(TM) Technologies and Growing Product Pipeline

SAN DIEGO, CA / ACCESSWIRE / August 24, 2022 / Ensysce Biosciences, Inc. ("Ensysce" or the "Company") (NASDAQ:ENSC) (OTC:ENSCW), a clinical-stage biotech company applying transformative chemistry to improve prescription drug safety to reduce abuse and overdose, today announced its participation in the following upcoming conferences: PAINWeek Conference 2022, September 6 - September 9, 2022, in Las Vegas, NV. Dr. Lynn Kirkpatrick, Chief Executive Officer, to chair a symposium and panel, entitled, "Severe Pain, Strategic Perspectives.

Ensysce Biosciences, Inc. Announces Participation in Upcoming Conferences

Completion of Clinical Portion Represents Critical Milestone Towards Commercialization Nasal Opioid Abuse Being Explored for PF614 Data From Trial Expected in September 2022 SAN DIEGO, CA / ACCESSWIRE / August 23, 2022 / Ensysce Biosciences, Inc. ("Ensysce" or the "Company") (NASDAQ:ENSC)(OTC PINK:ENSCW), a clinical-stage biotech company applying transformative chemistry to improve prescription drug safety to reduce abuse and overdose, today announced that it has successfully completed the clinical portion of study PF614-103, ‘A Randomized, Double-blind, Placebo- and Active-Controlled Crossover Study to Evaluate the Intranasal Abuse Potential of PF614 Compared with Immediate-Release Oxycodone and Placebo in Non-Dependent Recreational Opioid Users' being conducted by Dr. Glen Apseloff, from Ohio Clinical Trials, Inc. This trial is designed to test and confirm that manipulating and snorting PF614 will not result in subjects "liking" the product. Human Abuse Potential (HAP) studies are critical for gaining Abuse Deterrent labeling as outlined by the FDA.

Ensysce Biosciences Announces Completion of Clinical Portion of Human Abuse Potential Trial PF614-103

Mind Medicine MindMed

VistaGen Therapeutics

Penny stocks under $1 to watch this week. The post Penny Stocks To Buy?

Penny Stocks To Buy? 3 Under $0.99 For Your Watch List

~ Call to be Held Today, August 17, 2022 at 11am ET ~ SAN DIEGO, CA / ACCESSWIRE / August 17, 2022 / Ensysce Biosciences, Inc. ("Ensysce" or the "Company") (NASDAQ:ENSC)(OTC PINK:ENSCW), a clinical-stage biotech company applying transformative chemistry to improve prescription drug safety and performance focused on reducing abuse and overdose, today released an updated investor presentation to its investor relations website accessible via https://ir.ensysce.com/. The investor presentation has been updated to reflect the previously released data from the Part B, Bioequivalence (BE) arm of the PF614-102 study examining the Company's novel Trypsin-Activated Abuse-Protected (TAAP) opioid, PF614.

Ensysce Biosciences Releases Updated Investor Presentation Ahead of Corporate Update Call

Corporate Update Call to be Held Wednesday, August 17, 2022 SAN DIEGO, CA / ACCESSWIRE / August 11, 2022 / Ensysce Biosciences, Inc. ("Ensysce" or the "Company") (NASDAQ:ENSC, OTC PINK:ENSCW), a clinical-stage biotech company applying transformative chemistry to improve prescription drug safety and performance focused on reducing abuse and overdose, today reported financial results for the second quarter 2022. Dr. Lynn Kirkpatrick, Chief Executive Officer of Ensysce, commented, "With a recently completed $8 million financing, we are well positioned to advance our clinical trials.

Ensysce Biosciences Provides Business Update and Reports Second Quarter 2022 Financial Results

SAN DIEGO, CA / ACCESSWIRE / August 9, 2022 / Ensysce Biosciences, Inc. ("Ensysce" or the "Company") (NASDAQ:ENSC, OTC PINK:ENSCW), a clinical-stage biotech company applying transformative chemistry to improve prescription drug safety to reduce abuse and overdose, announced today that it has completed its previously announced private placement under a securities purchase agreement with institutional investors ("Investors") for senior secured convertible notes (the "Notes") and warrants exercisable for Ensysce common stock (the "Warrants") for an aggregate investment of $8 million. The final funding by the Investors of $4 million, prior to fees and offering expenses, was dated as of August 8, 2022, with funds received in full on August 9, 2022.

Ensysce Biosciences Announces Completion of $8 Million Convertible Note Financing

~ BE Study of PF614 Represents Critical Progress Toward FDA Approval ~ ~ Supports the 505(b)(2) Regulatory Path for Clinical Development of PF614 ~ SAN DIEGO, CA / ACCESSWIRE / July 27, 2022 / Ensysce Biosciences, Inc. ("Ensysce" or the "Company") (NASDAQ:ENSC)(OTC PINK:ENSCW), a clinical-stage biotech company applying transformative chemistry to improve prescription drug safety to reduce abuse and overdose, announced today the data from the Part B, Bioequivalence (BE) arm of the PF614-102 study examining the Company's novel Trypsin-Activated Abuse-Protected (TAAP) Opioid, PF614. The BE study follows the successful completion of the multi-ascending twice-daily dosing study of PF614 and compared the release of oxycodone from PF614 versus OxyContin® administered to subjects in both fasted and fed states.

Ensysce Biosciences Announces Positive Bioequivalence (BE) Study Data of Novel "TAAP" Opioid PF614 and Provides Timing of Corporate Update Call

~ Trial Designed to Test and Confirm Nasal Opioid Manipulation ~ SAN DIEGO, CA / ACCESSWIRE / July 13, 2022 / Ensysce Biosciences, Inc. ("Ensysce" or the "Company") (NASDAQ:ENSC)(OTC:ENSCW), a clinical-stage biotech company applying transformative chemistry to improve prescription drug safety and performance focused on reducing abuse and overdose, today announced the first patients dosed in the PF614-103 study, ‘A Randomized, Double-blind, Placebo- and Active-Controlled Crossover Study to Evaluate the Intranasal Abuse Potential of PF614 Compared with Immediate-Release Oxycodone and Placebo in Non-Dependent Recreational Opioid Users' is being conducted by Dr. Glen Apseloff, from Ohio Clinical Trials. This trial is designed to test and confirm that manipulating and snorting PF614 will not result in subjects liking the product as a recreational drug.

Ensysce Biosciences Announces Initial Patients Dosed of First Human Abuse Potential Study

Ensyce Biosciences (ENSC) stock is taking a beating on Friday after the clinical-stage biotech company announced $8 million in financing. The post Why Is Ensyce Biosciences (ENSC) Stock Down 27% Today?

Why Is Ensyce Biosciences (ENSC) Stock Down 27% Today?

~ Additional Funding from Investor Cohort Validates Company's Mission ~ SAN DIEGO, CA / ACCESSWIRE / July 1, 2022 / Ensysce Biosciences, Inc. ("Ensysce" or the "Company") (NASDAQ:ENSC)(OTC PINK:ENSCW), a clinical-stage biotech company applying transformative chemistry to improve prescription drug safety and performance focused on reducing abuse and overdose, announced today that it has entered into a securities purchase agreement with institutional investors ("Investors") in the form of senior secured convertible notes (the "Notes") and warrants exercisable for Ensysce common stock (the "Warrants") in a private placement for an aggregate investment of $8 million. The initial closing on June 30th provided $4 million on July 1st, prior to fees and offering expenses.

Ensysce Biosciences Secures $8 Million Convertible Note Financing

SAN DIEGO, CA / ACCESSWIRE / June 27, 2022 / Ensysce Biosciences, Inc. ("Ensysce" or the "Company") (NASDAQ:ENSC) (OTC:ENSCW), a clinical-stage biotech company applying transformative chemistry to improve prescription drug safety and performance focused on reducing abuse and overdose, today announced the Company has received a notice of award for the 4th year of funding of a multi-year grant from the National Institute on Drug Abuse (NIDA) for its Multi-Pill Abuse Resistance (MPAR™) Platform. The amount awarded is $2.8 million and the budget start date is July 1, 2022.

Ensysce Biosciences Receives Notice of Award for 4th Year of Funding for Its Multi-Pill Abuse Resistance (MPAR(TM)) Platform

- Shareholder Meeting to be Held on Thursday, June 23rd at 9:00 AM PT SAN DIEGO, CA / ACCESSWIRE / June 21, 2022 / Ensysce Biosciences, Inc. ("Ensysce" or the "Company") (NASDAQ:ENSC)(OTC PINK:ENSCW), a clinical-stage biotech company applying transformative chemistry to improve prescription drug safety and performance focused on reducing abuse and overdose, today reminds shareholders to vote on or before the upcoming annual shareholder meeting on Thursday, June 23rd at 9:00 AM PT/12:00 PM ET. Shareholders will be able to attend the 2022 Annual meeting virtually via live webcast by visiting https://agm.issuerdirect.com/ensc.

Ensysce Biosciences Reminds Shareholders to Vote At Upcoming 2022 Virtual Annual Shareholder Meeting

~ Nasal Opioid Abuse Being Explored for PF614 ~ ~ Data From Trial Expected in September 2022 ~ SAN DIEGO, CA / ACCESSWIRE / May 23, 2022 / Ensysce Biosciences, Inc. ("Ensysce" or the "Company") (NASDAQ:ENSC)(OTC PINK:ENSCW), a clinical-stage biotech company applying transformative chemistry to improve prescription drug safety and performance focused on reducing abuse and overdose, today announced the initiation of PF614-103, ‘A Randomized, Double-blind, Placebo- and Active-Controlled Crossover Study to Evaluate the Intranasal Abuse Potential of PF614 Compared with Immediate-Release Oxycodone and Placebo in Non-Dependent Recreational Opioid Users' is being conducted by Dr. Glen Apseloff, from Ohio Clinical Trials. This trial is designed to test and confirm that manipulating and snorting PF614 will not allow the drug abuser to achieve that desired state of euphoria.

Ensysce Biosciences Announces Initiation of First Human Abuse Potential Study

Corporate Update Call to be Held Tuesday, May 17, 2022 SAN DIEGO, CA / ACCESSWIRE / May 12, 2022 / Ensysce Biosciences, Inc. ("Ensysce" or the "Company") (NASDAQ:ENSC)(OTC PINK:ENSCW), a clinical-stage biotech company applying transformative chemistry to improve prescription drug safety and performance focused on reducing abuse and overdose, today reported financial results for the first quarter 2022. Dr. Lynn Kirkpatrick, Chief Executive Officer of Ensysce, commented, "The first few months of 2022 are off to an exciting start, evident in the most recent clinical results from trials PF614-102 and PF614-MPAR-101.

Ensysce Biosciences Provides Business Update and Reports First Quarter 2022 Financial Results

SAN DIEGO, CA / ACCESSWIRE / May 5, 2022 / Ensysce Biosciences, Inc. ("Ensysce" or the "Company") (NASDAQ:ENSC)(OTC PINK:ENSCW), a clinical-stage biotech company applying transformative chemistry to improve prescription drug safety and performance with a current focus on reducing abuse and overdose, today announced the release of its 2021 Annual Shareholder Letter authored by Chief Executive Officer, Dr. Lynn Kirkpatrick. To view the letter please visit https://ir.ensysce.com/.

Ensysce Biosciences Releases 2021 Annual Shareholder Letter

~ Results confirmed the safety and longer-lasting profile of PF614 versus OxyContin and provides first human data showing the potential for overdose protection with MPAR~ ~ Announces corporate update call timing ~ SAN DIEGO, CA / ACCESSWIRE / May 5, 2022 / Ensysce Biosciences, Inc. ("Ensysce" or the "Company") (NASDAQ:ENSC, OTC:ENSCW), a clinical-stage biotech company applying transformative chemistry to improve prescription drug safety and performance with a current focus on reducing abuse and overdose, today presented results from the clinical trials PF614-102 and PF614-MPAR-101 at the SMi Pain Therapeutics meeting in London, UK. PF614-102 The multi-ascending dose study (MAD) study examined 3 dose levels of PF614, a novel TAAP prodrug of oxycodone and the Company's lead candidate in Phase 2 development for the treatment moderate to severe pain.

Ensysce Biosciences Announces New Clinical Results from Trials PF614-102 and PF614-MPAR-101

SAN DIEGO, CA / ACCESSWIRE / April 20, 2022 / Ensysce Biosciences, Inc. ("Ensysce" or the "Company") (NASDAQ:ENSC)(OTC PINK:ENSCW), a clinical-stage biotech company applying transformative chemistry to improve prescription drug safety and performance with a current focus on reducing abuse and overdose, today announced the Company's participation in the upcoming conferences: The New York Academy of Sciences Advances in Pain meeting, New York, May 3 - 4, 2022 The Company's Senior VP of Clinical Development, Dr. William Schmidt will present, "The Next Generation Opioid Products for Moderate-Severe Pain" in a poster session on May 3, 2022. SMi's 22nd Annual Pain Therapeutics Conference, London, May 4 - 5, 2022 The Company's Chief Executive Officer, Dr. Lynn Kirkpatrick is a Featured Speaker discussing "The Next Generation of Opioids in Development" and will present Multi-Ascending Dose (MAD) clinical data on May 5, 2022 from the study: "A Phase 1b, Randomized, 2-Part Single-Center Study to Evaluate the Pharmacokinetics (PK) and Safety of Multiple-Ascending Oral Doses (MAD) of PF614 and the Food Effect and Bioavailability/BE of Single Oral Doses of PF614 Relative to OxyContin in Healthy Adult Subjects.

Dr. Lynn Kirkpatrick, Invited Speaker at SMi 22nd Annual Pain Therapeutics Conference in London UK

SAN DIEGO, CA / ACCESSWIRE / April 18, 2022 / Ensysce Biosciences, Inc. ("Ensysce" or the "Company") (NASDAQ:ENSC)(OTC PINK:ENSCW), a clinical-stage biotech company applying transformative chemistry to improve prescription drug safety and performance with a current focus on reducing abuse and overdose, today announced the appointment of Dr. Nily Osman as Chief Medical Officer effective April 18, 2022. Dr. Osman will succeed Dr. William Schmidt as he transitions to Senior VP of Clinical Development and continues his role on the Company's clinical advisory board.

Ensysce Biosciences Announces Appointment of Dr. Nily Osman as Chief Medical Officer

BitNile Holdings

RLX Technology

Are these penny stocks on your list following the monetary policy shift? The post Penny Stocks to Watch as the Fed Tightens its Monetary Policy  appeared first on Penny Stocks to Buy, Picks, News and Information | PennyStocks.com.

Penny Stocks to Watch as the Fed Tightens its Monetary Policy

Ensysce Biosciences, Inc. (ENSC) CEO Dr. Lynn Kirkpatrick on Corporate Update Call (Transcript)

~ Corporate Update Call to be Held Wednesday, April 6, 2022 ~ ~ Corporate Update Call to be Held Wednesday, April 6, 2022 ~

Ensysce Biosciences Provides Business Update and Reports Fourth Quarter and Full Year 2021 Financial Results

SAN DIEGO, CA / ACCESSWIRE / March 24, 2022 / Ensysce Biosciences, Inc. ("Ensysce" or the "Company") (NASDAQ:ENSC)(OTC PINK:ENSCW), a clinical-stage biotech company applying transformative chemistry to improve prescription drug safety and performance with a focus on reducing abuse and overdose while providing relief for those with severe pain, today announced plans to release fourth quarter and full year 2021 financial results after close of market on Thursday, March 31, 2022. Corporate Update Conference Call Management will host a corporate update conference call on Wednesday, April 6, 2022, at 11:00 a.m.

Ensysce Biosciences Announces Fourth Quarter and Full Year 2021 Earnings Release Date and Timing of Corporate Update Call

SAN DIEGO, Feb. 23, 2022 (GLOBE NEWSWIRE) -- Ensysce Biosciences, Inc. (“Ensysce” or the “Company”) (NASDAQ: ENSC, OTC: ENSCW), a clinical-stage biotech company applying transformative chemistry to improve prescription drug safety and performance with a focus on reducing abuse and overdose while providing relief for those with severe pain, today announced management's participation in the 34th Annual Roth Conference being held March 13-15, 2022 at the Ritz Carlton, Laguna Niguel in Dana Point, California.

News for Ensysce Biosciences Stock (ENSC)